التفاصيل البيبلوغرافية
| العنوان: |
Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: cross-sectional and longitudinal studies |
| المؤلفون: |
Musa, Sanjin, Baralija, Elma Catovic, Sawin, Veronica Ivey, Nardone, Anthony, Palo, Mirza, Skocibusic, Sinisa, Blazevic, Mia, Lagarija, Seila Cilovic, Ahmetovic-Karic, Gorana, Ljuca, Alma, Dostovic-Halilovic, Sanela, Nedic, Rozalija, Subissi, Lorenzo, Ibrahim, Rawi, Boshevska, Golubinka, Bergeri, Isabel, Pebody, Richard, VAUGHAN, Aisling |
| بيانات النشر: |
Authorea, Inc. |
| سنة النشر: |
2022 |
| المجموعة: |
The Winnower (via CrossRef) |
| الوصف: |
Background Sarajevo Canton in the Federation of Bosnia and Herzegovina has recorded several waves of high SARS-CoV-2 transmission and has struggled to reach adequate vaccination coverage. We describe the evolution of infection- and vaccine-induced SARS-CoV-2 antibody response and persistence. Methods We conducted repeated cross-sectional analyses of blood donors aged 18-65 years in Sarajevo Canton in November-December 2020 and 2021. We analyzed serum samples for anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodies. To assess immune durability, we conducted longitudinal analyses of seropositive participants at 6 and 12 months. Results 1015 participants were included in Phase 1 (November-December 2020), and 1152 in Phase 2 (November-December 2021). Seroprevalence increased significantly from 19.2% (95% CI: 17.2-21.4%) in Phase 1 to 91.6% (95% CI: 89.8-93.1%) in Phase 2. Anti-S IgG titers were significantly higher among vaccinated (58.5%) than unvaccinated infected participants across vaccine products (p<0.001), though highest among those who received an mRNA vaccine. At 6 months, 78/82 (95.1%) participants maintained anti-spike seropositivity; at 12 months, 58/58 (100.0%) participants were seropositive and 33 (56.9%) had completed the primary vaccine series within 6 months. Among 11 unvaccinated participants who were not reinfected at 12 months, anti-S IgG declined from median 770.1 (IQR 615.0-1321.7) to 290.8 (IQR 175.7-400.3). Anti-N IgG antibodies waned earlier; from 35.4% seropositive at 6 months to 24.1% at 12 months. Conclusions SARS-CoV-2 seroprevalence increased significantly over 12 months from end of 2020 to end of 2021. Although individuals with previous infection may have residual protection, COVID-19 vaccination is vital to strengthening population immunity. |
| نوع الوثيقة: |
other/unknown material |
| اللغة: |
unknown |
| DOI: |
10.22541/au.166608003.39636815/v1 |
| الإتاحة: |
https://doi.org/10.22541/au.166608003.39636815/v1Test |
| رقم الانضمام: |
edsbas.9CF2848D |
| قاعدة البيانات: |
BASE |
